Curriculum Vitae Dr Natalie Matosin BMSc (Hons), PhD

CAREER TRAJECTORY

Apr 2018 – current        Research Fellow (see Fellowships for funding information) University of Wollongong, School of Biological Sciences, Illawarra Health and Medical Institute and Molecular Horizons Institute

Apr 2016 – current        Research Fellow (see Fellowships for funding information) Max Planck Institute of Psychiatry, Department of Translational Psychiatry Research. Mentor: Elisabeth B Binder MD PhD

May 2015 – Apr 2018    Postdoctoral Associate (12 months) / Research Fellow University of New South Wales (UNSW) School of Psychiatry, Research Unit for Schizophrenia Epidemiology. Mentor: Melissa J Green PhD

Dec 2014 – May 2015   Career Launch Fellow University of Wollongong (UOW) Centre for Translational Neuroscience. Mentor: Xu-Feng Huang MD PhD

Jan 2012 – Dec 2014    PhD Student University of Wollongong (UOW) Centre for Translational Neuroscience. Mentors: Kelly A Newell PhD and Dr Francesca Fernandez PhD

Jan 2012 – Dec 2014    Laboratory Manager. UOW Centre for Translational Neuroscience. Laboratory Head: Xu-Feng Huang MD PhD

Jun – Jul 2014 &Sep – Oct 2013   Research Intern Max Planck Institute for Psychiatry. Mentor: Dr Mathias V Schmidt PD PhD (4 months duration)

Jan 2011 – Dec 2013    Graduate Teaching Assistant. Demonstrator for undergraduate Physiology (1st year), Biochemistry (2nd year), Pathophysiology (3rd year) and Neuroanatomy (3rd year). Schools of Medicine and Biological Sciences, UOW

 

EDUCATION

2012 – 2015 Doctor of Philosophy Thesis: Exploring mGluR5 dysregulation in schizophrenia: from gene to protein. School of Medicine, University of Wollongong Australia

2007 – 2011 Bachelor of Medical Science, Honours (Class 1, ranked 1). Thesis: NMDA Receptor and Metabotropic Glutamate Receptor 5 Expression in the Dorsolateral Prefrontal Cortex in Schizophrenia. School of Medicine, University of Wollongong Australia

FUNDING TOTAL >800,000 AUD

RESEARCH GRANTS (>158,000 AUD)

2018     IHMRI Young Investigator Grant 20,000 AUD (10,000 AUD in kind; 20 percent success). Matosin N. The Trauma and Refugee Intervention Project. Illawarra Health and Medical Research Institute

2017     NARSAD Young Investigator Grant 70,000 USD (104,000 AUD) Matosin N. FKBP5 dual disinhibition: a trans-diagnostic marker to delineate a subtype of psychiatric cases? Brain & Behavior Research Foundation.

2016     Support for Research Costs 19,600 EUR (29,300 AUD) Matosin N, Binder EB. Harnessing the human postmortem brain to elucidate changes in FKBP5 in the neuropathology of severe psychiatric disorder. Alexander von Humboldt Foundation.

2015     Daniel Beck Memorial Award 2,824 AUD Matosin N. Influence of genetic variants in GRM5 on protein in the postmortem schizophrenia brain. Research Grant, Schizophrenia Research Institute.

2014     A.M. Wood Postgraduate Award for Schizophrenia Research 5,000 AUD
Matosin N. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Research Grant, Schizophrenia Research Institute.

2013     Grant-in-Aid 3,480 AUD. Matosin N, Fernandez-Enright F, Newell KA.  Investigation of Metabotropic Glutamate Receptor 5 Gene GRM5 polymorphisms in the genetic vulnerability of schizophrenia. Research Grant, Schizophrenia Research Institute.

2013     Grant-in-Aid 16,100 AUD. Catts VS, Weickert CS, Newell KA, Zhang Y, Matosin N. Neurobiology of cortical thinning in schizophrenia. Research Grant, Schizophrenia Research Institute.

FELLOWSHIPS (>650,000 AUD)

2016     NHMRC CJ Martin Overseas Biomedical Fellowship (21% success) Australian National Health and Medical Research Council 392,052 AUD, 100% fte 4 years. These Fellowships are offered to a limited number of persons of outstanding ability. The full time Fellowships are awarded for a period of four years, the first two of which are spent overseas and the remaining two in Australia.

2016     Alexander Von Humboldt Research Fellowship (25% success) Alexander Von Humboldt Foundation 63,600 EUR (95,000AUD), 100% fte 2 years. Awarded to highly-qualified early career researchers from abroad to spend extended periods of research (6–24 months) in Germany. Scientists and scholars from all disciplines and countries may apply.

2016     IBRO Research Fellowship (2% success) International Brain Research Organisation (IBRO) 35,000 EUR (52,300AUD), 100% fte 1 year. Only eight fellowships are offered annually to international applicants under the age of 45. These fellowships aim to support and improve the global advancement of neuroscience research.

2015     Research Career Launch Fellowship University of Wollongong, 12,295 AUD, 100% fte 6 months. Awarded to jump-start the career of selected outstanding young researchers, by supporting them after the submission of their doctoral thesis. Awarded Dec 2014.

2013     Travelling Fellowship. Disease Models and Mechanisms (DMM) 2,500 GBP (4,100 AUD), 100% fte 6 weeks. To participate in international internship at the Max Planck Institute of Psychiatry, Munich 2013. The Company of Biologists UK. Awarded 2013.

2012     Ian Scott Scholarship. Australian Rotary Health 13,041 AUD, 15% fte 3 years. PhD top-up scholarship; awarded based on academic record, scientific excellence, feasibility of proposed research, quality of supervisors and relevance to the Australian community.

2012     Australian Postgraduate Award. Australian Department of Education and Training 73,773 AUD, 85% fte 3.5 years. Stipend to support doctoral candidates throughout the duration of their PhD studies.

2011     Health and Behavioural Sciences Research Scholarship . Faculty of Health and Behavioural Sciences, University of Wollongong 5,000 AUD, 100% fte 12 months. Competitive Honours research scholarship to financially assist outstanding Honours students, and to encourage growth in research outside intended Honours program.

AWARDS 

2019     Young Tall Poppy Award (NSW). Australian Institute of Policy and Science. These prestigious awards recognise the achievements of Australia’s outstanding young scientific researchers based on outstanding research, academic achievement and excellence in communication and community engagement to promote an understanding of science. 120 applications, 11 awarded to applicants up to 10 years post-PhD.

2019     Dame Bridget Ogilvie Career Advancement Scholarship 1,500 AUD. Illawarra Health and Medical Research Institute. The Career Advancement Scholarships provide funding to support female researchers at any stage of their career to assist financially with an opportunity to enhance their career profile.

2018     Impact Maker Award. University of Wollongong. Recognized as a young leader whose work is currently or likely to deliver tangible, positive changes at a global scale.

2018     Biological Psychiatry Australia – Early Career Network Award 1,100 AUD. Biological Psychiatry Australia. Travel award for collaborative visit to lab interstate.

2017     TEDx Speaker. TEDx Hamburg, June 2017. Talk on the importance of science communication and dissemination.

2017     Forbes 30 Under 30, 2017. Forbes Magazine, Europe Class of Science and Healthcare

2017     ACNP Travel Award 4000 USD. American College of Neuropsychopharmacology

2017     Alies Muskin Career Development Award. Anxiety and Depression Association of America

2016     SOBP International Early Career Investigator Award 2,000 USD. Society of Biological Psychiatry

2015     Top 15 Australian Graduate to Watch in 2015. Women’s Agenda (Australian news service)

2015     Global Challenges Award 2,000 AUD. Global Challenges Program UOW

2014     FENS/IBRO Young Investigator Award – International 750 EUR. Federation of European Neuroscience Society/International Brain Research Organization

2013     Young Investigator Research Excellence Award. 12th Biennial Australasian Schizophrenia Conference]

2013     Young Investigator of the Year Award 3,000 AUD. Schizophrenia Research Institute

2013     Student of the Year Award for Best Publications 500 AUD. Centre for Translational Neuroscience UOW

2013     Graduate Student Travel Fellowship 3,500 AUD. Associate Dean of Research UOW

2012     ANS Young Researcher Award for Travel 200 AUD. Australian Neuroscience Society 

2011     Dean’s Merit Award for High-Level Undergraduate Performance. Faculty of Health and Behavioural Sciences UOW

 

PUBLICATION RECORD

29 publications: 15 first author; 5 last author; 5 corresponding author, 414 citations, h index = 12 on 11/11/19

  1. Kaul D, Schwab S.G., Matosin N*. Impacts of Stress on Brain Cytoarchitecture in the Development of Severe Psychiatric Disorders. 2019. https://psyarxiv.com/f3nj8 *Corresponding author
  2. Kalfic K, Mitchell G, Ooi L, Schwab SG, Matosin N*. Overcoming the deficiency of refugee mental health research. 2019. psyarxiv.com/g5rx7. *Corresponding author
  3. Matosin N, Halldorsdottir T, Binder EB. Understanding the molecular mechanisms underpinning G×E interactions in psychiatric disorders: the FKBP5 model. Biological Psychiatry. 2018. 83(10): 821-830 [IF=11.212]
  4. Matosin N, Newell KA, Quidé Y, Teroganova N, Andrews JL, Green MJ, Fernandez-Enright F. Effects of common GRM5 genetic variants on cognition, hippocampal volume and mGluR5 protein levels in schizophrenia. Brain Imaging and Behavior, 2018. 12(2): 509-517. [IF=3.667]
  5. Quidé Y, Matosin N, Atkins JR, Cairns MJ, Laurens KR, Jablensky A, Carr VJ, Green MJ. Common variation in ZNF804A (rs1344706) is not associated with brain morphometry in schizophrenia or healthy participants. Progress in Neuropsychopharmacology & Biological Psychiatry. 2018. 82(2): 12-20 [IF=3.689]
  6. Andrews JL, Newell KA, Matosin N, Huang XF, Fernandez-Enright F. Perinatal administration of phencyclidine alters expression of Lingo-1 signaling pathway proteins in the prefrontal cortex of juvenile and adult rats. Neuronal Signaling. [no IF] In press.
  7. JS Lum, SJ Millard, Frank E, Matosin N, Huang XF, Ooi L, Newell KA. Chronic Adolescent CDPPB Treatment Alters Short-Term, but not Long-Term, Glutamatergic Receptor Expression. Neurochemical Research. 2018, Epub ahead of press. [IF=2.125]
  8. Matosin N*, Cruceanu C*. Stress-related memory impairments are modulated by the synergistic action of stress hormones: implications for PTSD. The Journal of Neuroscience. 2017. 37(16) 4225-4227. [IF=5.924] *Equal first/last and corresponding author
  9. Matosin N, Cruceanu C, Binder EB. Preclinical and clinical evidence of DNA methylation changes in response to trauma and chronic stress. Chronic Stress. 2017. 1:1-20. [no IF]
  10. Matosin N*, Fernandez-Enright F, Lum JS, Newell KA. Shifting towards a model of mGluR5 dysregulation in schizophrenia: consequences for future schizophrenia treatment. Invited article for Special Edition “mGluRs: 5 years on”, Neuropharmacology. 2017. 115:73-91 [IF=5.106]. *Corresponding author
  11. Matosin N, Green MJ, Newell KA, Fernandez-Enright F. Effects of GRASP variation on memory in psychiatrically healthy individuals and cognitive dysfunction in schizophrenics. Gene Reports. 2017. 6:121-127. [no IF]
  12. Cruceanu C, Matosin N, Binder EB. Interactions of early life-stress with the genome and epigenome: from prenatal stress to psychiatric disorders. Current Opinion in Behavioral Sciences. 2017. 14:167-171. [no IF]
  13. Andrews JL, Goodfellow F, Matosin N, Snelling MK, Newell KA, Huang XF, Fernandez-Enright F. Alterations of Ubiquitin Related Proteins in the Pathology and Development of Schizophrenia: Evidence from Human and Animal Studies. Journal of Psychiatry Research. 2017. 90:31-39. [IF=3.957] 
  14. Matosin N, Siegel SJ. mGluR5 as a point of Convergence for models of OCD and ASD. Biological Psychiatry. 2016. 80(7):504-6. [IF=11.212]
  15. Matosin N*, Fernandez-Enright F, Lum JS, Engel M, Andrews J, Gassen NC, Wagner KV, Schmidt MV, Newell KA. Molecular evidence of synaptic pathology in CA1 in schizophrenia. NPJ Schizophrenia. 2016. 2:16022. [no IF]. *Corresponding author
  16. Matosin N, Green MJ, Andrews JL, Newell KA, Fernandez-Enright F. Possibility of a sex-specific role for a genetic variant in FRMPD4 in schizophrenia, but not cognitive function. NeuroReport. 2016. 27(1):33-8. [IF=1.644]
  17. Lum JS, Fernandez-Enright F, Matosin N, Andrews JL, Huang XF, Ooi L, Newell KA. Neurodevelopmental expression of dimeric and monomeric group 1 mGluRs: relevance to schizophrenia pathogenesis and treatment. Scientific Reports. 2016. 6:34391. [IF=5.578]
  18. Engel M, Snikeris P, Matosin N, Newell KA, Huang XF, Frank E. mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia. Psychopharmacology. 2016. 233(8):1349-59. [IF=3.875]
  19. Matosin N, Fernandez-Enright F, Fung, SJ, Lum JS, Engel M, Andrews JL, Huang XF, Weickert CS, Newell KA. Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation. Acta Neuropathologica. 2015. 130(1):119-129. [IF=18.174]
  20. Matosin N, Fernandez-Enright F, Lum JS, Andrews JL, Engel M, Huang XF, Newell KA. Metabotropic glutamate receptor 5 and its trafficking molecules, Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia. Schizophrenia Research. 2015. 166(1-3):212-218. [IF=4.748]
  21. Wagner KV, Hartmann J, Labermaier C, Häusl AS, Zhao G, Harbich D, Schmid B, Wang XD, Santarelli S, Kohl C, Gassen NC, Matosin N, Schieven M, Webhofer C, Turck CW, Lindemann L, Jaschke G, Wettstein JG, Rein T, Müller MB, Schmidt MV. Homer1/mGluR5 signaling moderates vulnerability to chronic social stress. Neuropsychopharmacology. 2015. 40(5):1222-1233. [IF=7.833]
  22. Andrews JL, Newell KA, Matosin N, Huang XF, Fernandez-Enright F. Alterations of p75 neurotrophin receptor and myelin transcription factor 1 in the hippocampus of perinatal phencyclidine treated rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2015. 63(3):91-97. [IF=3.689]
  23. Andrews JL, Newell KA, Matosin N, Huang XF, Fernandez-Enright F. NMDA receptor antagonism by phencyclidine reduces WASP and WAVE1 protein expression and reduces levels of myelination marker levels in the prefrontal cortex of rats. Journal of Pharmaceutics & Pharmacology. 2015. 3(1):8. [IF=2.264]
  24. Matosin N, Fernandez-Enright F, Frank E, Deng C, Wong J, Huang XF, Newell KA. Metabotropic glutamate receptors mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and non-psychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics. Journal of Psychiatry and Neuroscience. 2014. 39(6):407-16. [IF=7.492]
  25. Matosin N*, Frank E, Engel M, Lum JS, Newell KA. EDITORIAL. Negativity towards negative results: a discussion of the disconnect between scientific worth and scientific culture. Disease Models & Mechanisms. 2014. 7(2):171-173. [IF=5.537]. *corresponding author
  26. Newell KA, Matosin N. Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics. BMC Psychiatry. 2014. 14:23. [IF = 2.237]
  27. Newell KA, Matosin N, Lum J. Chapter 5: Metabotropic glutamate receptors in the pathophysiology and treatment of schizophrenia and major depression. Metabotropic Glutamate Receptors: Molecular Mechanisms, Role in Neurological Disorders and Pharmacological Effects. Nova Publishers. 2014. Editor: Foster M Olive. ISBN: 978-1-63117-451-3
  28. Matosin N, Newell KA. Metabotropic Glutamate Receptor 5 in the Pathology and Treatment of Schizophrenia. Neuroscience and Biobehavioural Reviews. 2013. 37(3):256-268. [IF = 10.284]
  29. Matosin N, Frank E, Deng C, Huang XF, Newell KA. Metabotropic Glutamate Receptor 5 Binding and Protein Expression in Schizophrenia and Following Antipsychotic Drug Treatment. Schizophrenia Research. 2013. 146(1-3):170-176. [IF=4.590]


SYMPOSIUM ORGANISATION

2016     Matosin N (chair), Meador-Woodruff JH (co-chair).  Harnessing the Postmortem Human Brain to Study Severe Psychiatric Disorders: Methodological Innovations and Paradigm Shifts. Society of Biological Psychiatry, Atlanta, USA. May 12-14.

2013     Matosin N (chair) Molecular Biology and Psychosis. 12th Biennial Australasian Schizophrenia Conference, Melbourne Australia. May 13-14.


CONFERENCE TALKS

  • Matosin N. The postmortem human brain to characterize novel drug targets for psychiatric disorders: using FKBP5 as an example. Society of Biological Psychiatry, New York, USA. May 10-12, 2018.
  • Matosin N. 10 things I wish I knew before: a career in academic science. Science+ Conference, Bilbao, Spain. Sept 18-20, 2017.
  • Matosin N. “Getting Science from Einstein to your Granny: How Society Shapes Science.” TEDx Conference, June 30, 2017. TEDx Hamburg, Germany.
  • Matosin N. FKBP5 dual disinhibition: a trans-diagnostic marker to delineate a subtype of psychiatric cases? Alies Muskin Career Development Program, Anxiety and Depression Association of America Conference, San Francisco April 10, 2017.
  • Matosin N (chair), Meador-Woodruff JH (co-chair). Harnessing the Postmortem Human Brain to Study Severe Psychiatric Disorders: Methodological Innovations and Paradigm Shifts. Society of Biological Psychiatry, Atlanta, USA. May 12-14. 2016
  • Matosin N, Quidé Y, Gould IC, Teroganova N, Andrews JL, Newell KA, Green MJ, Fernandez-Enright F. Associations of novel genetic variants in GRM5 with schizophrenia, cognition and hippocampal volume. Biological Psychiatry Australia Meeting, Coogee, Australia September 21-22, 2015.
  • Matosin N, Green MJ, Andrews JL, Newell KA, Fernandez-Enright F. Association of a genetic variant in FRMPD4, encoding for the multi-scaffolding protein Preso1, with schizophrenia and cognition. Australian Society for Medical Research NSW Scientific Meeting, Sydney, June 1, 2015.
  • Matosin N. “mGluR5 dysregulation in schizophrenia”, Rotary Health Media Training Conference, Adelaide University, December 2014.
  • Matosin N, Fernandez F, Huang XF, Newell KA. Evidence of mGluR5 dysregulation in schizophrenia. Australian Neuroscience Society 34th Annual Meeting, Adelaide Australia, January 28-31 2014.
  • Matosin N, Frank E, Fernandez F, Deng C, Wong J, Huang XF, Newell KA. An Analysis of Metabotropic Glutamate Receptors 2/3 and 5 in Schizophrenia, Major Depression and Bipolar Disorder from the Stanley Neuropathology Consortium. Australian Neuroscience Society 33rd Annual Meeting, Melbourne Australia, February 3-6 2013.
  • Matosin N. Wollongong Centre SRI update: Schizophrenia Research Institute Summit, September 2012.
  • Matosin N, Newell KA. mGluR5 expression in the DLPFC of schizophrenia. Neuroscience Colloquium 2012, Australian National University, NSW, Australia, March 10-11 2012

INVITED TALKS

  • Matosin N. “How gene x stress interactions contribute to the development of mental illness: focus on FKBP5.” June 2018, James Cook University, QLD Australia.
  • Matosin N. “Exploring FKBP5 in the neuropathology of severe psychiatric disorders: evidence from the postmortem human brain.” February 26, 2018. Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig Germany.
  • Matosin N. “Role of the genome and epigenome in the regulation of stress genes: mapping FKBP5 interactions to the brain”. Lieber Institute for Brain Development (LIBD), John Hopkins University. Baltimore, December 9, 2016.
  • Matosin N. “The role of FKBP5 in the brain: implications for severe psychiatric disorders”. University of Southern California, 2016.
  • Matosin N. “The role of FKBP5 in the brain: implications for severe psychiatric disorders”. Faculty of Science, University of Wollongong. Wollongong, November 30, 2016.
  • Matosin N. “Early Career Fellowships: Strategies to Blueprints”. University of New South Wales, Sydney, November 17, 2016.
  • Matosin N. “Using the postmortem human brain to study psychiatric disorders: examples using mGluR5 in schizophrenia”. University of Sydney, August 13, 2015.
  • Matosin N. “How is mGluR5 dysregulated in schizophrenia?”: Australian Rotary Health, Parramatta committee meeting, November 2014.
  • Matosin N. Schizophrenia Research Institute’s Spark of Genius fundraising/community engagement event: Guest scientist interviewed by Prof. Vaughan Carr, SRI Scientific Director, 2014.
  • Matosin N. Vote of Thanks, Graduation Ceremony, School of Health Sciences, November 2011.

 

SCIENTIFIC SERVICE ROLES

Editorial Boards: PLOS One, Academic Editor

Ad hoc reviewer: Biological Psychiatry, Molecular Psychiatry, Schizophrenia Bulletin, Schizophrenia Research, Epigenomics, Nature Chemical Biology, European Psychiatry, Psychiatry Research: Neuroimaging, Psychiatry Research, Frontiers in Cellular Neuroscience, Drug Design Development and Therapy.

Panel Member: NHMRC Investigator Grant Scheme 2019 (relinquished due to caring responsibilities)

Conference Organisation/Service

  • 2017-18 Essay Judge, American Society of Human Genetics, March.
  • 2015     Round Table Speaker “Social Media and Your Career”, Early Career Development Day, Australian Society for Medical Research, November 2015.
  • 2015     Poster Judge, Biological Psychiatry Australia Scientific Conference, September.
  • 2015     Conference Committee Member, Australian Society for Medical Research
  • 2015     Abstract Marker and Poster Judge, Australian Society for Medical Research NSW Scientific Conference, June.

Organisational Roles:

  • MIND The GaP Advisory Board Member and Illawarra Health and Medical Research Institute Representative. MTG is a mental health and wellbeing facility that aims to prevent suicide, traumatic stress responses and improve community resilience in the Nowra/Shoallhaven area. My role on the MTG Advisory Board is to facilitate research and consult on research practice with the facility. 2019 – current
  • Equity, Diversity and Inclusion Committee Member Illawarra Health and Medical Research Institute. My role on this committee is to improve diversity and inclusion within the institute and to take institute members’ concerns to the board for discussion and action. 2019 – current
  • Australian Society for Medical Research, Media and Communications Officer. 2014-2016.

Memberships: Society of Biological Psychiatry, Anxiety and Depression Association of America, American College of Neuropsychopharmacology Awardee (path to appointed associate membership), Forbes Under 30 community, National Geographic Women of Impact community, NYAS 1000 girls 1000 Futures Mentorship Program 


TRAINING COURSES

  • 2019 Genomes and Biodiversity: Research and Career Development workshop, Australian Academy of Sciences, University of Sydney Nov 20-22 2019
  • 2016 RNA sequencing library preparation: How low can you go? EMBL, Heidelberg Germany
  • 2015 Human Genome Bioinformatics Workshop, University of New South Wales.
  • 2016 First level German language course, Goethe Institute Munich, Germany.
  • 2015 Introduction to R and NGS Using R workshop, Bioplatforms Australia, Macquarie University.
  • 2015 Approaching the Supervision Experience, University of New South Wales Workshop.
  • 2015 Early Career Development Workshop, Australian Society for Medical Research, UNSW Lowy Building.
  • 2014 Media Training Workshop, Australian Rotary Health.
  • 2014 Certificate in German 1language, WEA Illawarra, Worker’s Educational Association/Community College Network.
  • 2012-14 – Graduate Certificates in Project Management, Entrepreneurship and Research Commercialisation. Australian Technology Network. 

MEDIA

Radio interviews:

  • ABC NSW Statewide Drive, live interview with Fiona Wyllie regarding inclusion in the Forbes 30 under 30 Europe list. 5:30pm, 24th January 2017.
  • ABC Illawarra Drive, interviews with Lindsay McDougall. 1 x 2018 and 2 x 2019

News Articles:

OUTREACH and SOCIAL MEDIA

  • Contributor:  The Conversation (theconversation.com/au).
  • Mentor:  Mentor for the New York Academy of Science, 1000 Girls 1000 Futures Program,
  • Media:  Media coverage can be viewed here
  • Blog:  www.nataliematosin.com; over 3000 regular readers
  • Lab website: https://matosinlab.wordpress.com/
  • Twitter:  @postmortemgirl. Currently 4,630+ followers
  • Instagram:   @thestressscientist. Currently 1000+ followers